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Abstract 
Background: Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and 
standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate 
for immunotherapy by reason of their expression of shared tumor‑associated antigens (TAAs) and private mutated neo‑
antigens (NeoAgs) and the recognition of the tumor by the immune system. Additionally, the presence of intraepithelial 
tumor infiltrating lymphocytes (TILs) is associated with improved progression‑free and overall survival of patients with 
ovarian cancer. The aim of active immunotherapy, including vaccination, is to generate a new anti‑tumor response and 
amplify an existing immune response. Recently developed NeoAgs‑based cancer vaccines have the advantage of being 
more tumor specific, reducing the potential for immunological tolerance, and inducing robust immunogenicity.
Methods: We propose a randomized phase I/II study in patients with advanced ovarian cancer to compare the 
immunogenicity and to assess safety and feasibility of two personalized DC vaccines. After standard of care surgery 
and chemotherapy, patients will receive either a novel vaccine consisting of autologous DCs pulsed with up to ten 
peptides (PEP‑DC), selected using an agnostic, yet personalized, epitope discovery algorithm, or a sequential combi‑
nation of a DC vaccine loaded with autologous oxidized tumor lysate (OC‑DC) prior to an equivalent PEP‑DC vaccine. 
All vaccines will be administered in combination with low‑dose cyclophosphamide. This study is the first attempt to 
compare the two approaches and to use NeoAgs‑based vaccines in ovarian cancer in the adjuvant setting.
Discussion: The proposed treatment takes advantage of the beneficial effects of pre‑treatment with OC‑DC prior to 
PEP‑DC vaccination, prompting immune response induction against a wide range of patient‑specific antigens, and 
amplification of pre‑existing NeoAgs‑specific T cell clones.
Trial registration This trial is already approved by Swissmedic (Ref.: 2019TpP1004) and will be registered at http://www.
clini caltr ials.gov before enrollment opens.
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Background
Ovarian cancer (OC) is the primary cause of gynecologic 
cancer-related deaths, with more than 300,000 expected 
new cases, and more than 190,000 estimated deaths 
worldwide in 2020 [1]. New treatment approaches for 
ovarian cancer care are urgently needed, as current thera-
pies, including cytoreductive surgery and platinum-based 
chemotherapy, do not cure most patients with advanced 
epithelial ovarian cancer [2].
The host immune system can recognize and target 
ovarian cancer [3], in which a variety of tumor-associated 
antigens (TAAs) have been demonstrated (HER-2/neu 
[4]; p53 [5, 6]; the folate binding protein [7], sialyated 
TN [8], MUC-1 [9], NY-ESO-1 [10] or mesothelin [11] 
among others). Furthermore, patients presenting TILs 
in their ovarian cancer tissue show longer progression-
free and overall survival (PFS and OS) [3], indicating that 
tumor growth is under the surveillance of the immune 
system, and suggesting that ovarian cancer is a good can-
didate for immunotherapy [12]. Nevertheless, the efficacy 
of immunotherapy may be decreased by the involvement 
of various mechanisms of immune evasion in the tumor 
microenvironment including high expression of PD-L1 
[13], production of IDO [14], recruitment of regulatory 
T-cells (Tregs) [15, 16], or local and systemic dysfunction 
of plasmacytoid dendritic cells (pDCs) [17].
Cancer vaccines
Cancer vaccines are intended to “educate” the patient’s 
own immune system to generate effector T-cells spe-
cifically for tumor cells to be detected and destroyed. A 
tailored cancer vaccine aims to target multiple patient-
specific tumor antigens and reduce side-effects by pro-
tecting normal tissue and keeping tumors under immune 
memory regulation for as long as possible [18]. Den-
dritic cell (DC)-based vaccines are a particularly attrac-
tive option for immunotherapy, due to their low toxicity 
profile, lack of invasive procedures and their potential to 
induce long-term effects through immunological mem-
ory [19]. DCs are unique immune cells responsible for 
processing and presenting cancer antigens, and are capa-
ble of initiating and regulating both innate and adaptive 
immunity [20]. DCs can present endogenous antigens 
as human leukocyte antigen (HLA) class I peptides and 
exogenous antigens as either HLA class II peptides or 
HLA class I peptides by cross presentation, thus effec-
tively inducing antigen-driven T-cell responses. Mono-
cyte-derived human DCs pulsed with TAAs have been 
extensively used for clinical therapies against malignan-
cies [21]. Unfortunately, DC vaccines have demonstrated 
limited efficacy in patients with advanced recurrent dis-
ease [22]. Some promising results however suggest a need 
for further optimization, including combination of differ-
ent immunotherapy technologies and multiple antigens.
Key factors leading to the poor immune response in 
ovarian cancer include lack of well-characterized tumor 
antigens, molecular heterogeneity, selective tumor anti-
gen-loss (immuno-editing) and the immunosuppressive 
nature of the tumor microenvironment [23]. When vac-
cines target defined non-mutated self-antigens or shared 
antigens that are overexpressed in the tumor, vaccine effi-
cacy is often low because T cell reactivity to self-antigens 
is naturally reduced due to central tolerance [24]. Alter-
natively, neoantigens (NeoAgs) that arise from somatic 
DNA alterations as a result of genetic instability are can-
cer-specific and can be strongly immunogenic [25]. Neo-
Ags are likely to be effective targets for tumor infiltrating 
T cells and can lead to successful immunotherapy treat-
ments [26], hence synthetic vaccines targeting patient-
specific NeoAgs can display increased efficacy against 
tumors with moderate or high mutation load. Three 
recent phase I studies using personalized NeoAg-based 
vaccines reported immunogenicity and interesting clini-
cal safety and efficacy results [27–30].
Whole tumor lysate vaccines
An alternative source of personalized antigens is the 
whole tumor lysate. In the case of ovarian cancer, tumor 
cells can be easily recovered by cytoreductive surgery 
and tumor antigens can be obtained directly from the 
patient’s own tumor cells by preparing a tumor lysate that 
contains both the TAAs and the private NeoAg without 
the hurdles of target identification and preparation [31]. 
The immunogenicity of whole-tumor antigen vaccines 
can be enhanced by different tumor lysate preparation 
methods [31, 32]. During the final culture stage, tumor 
lysate is loaded onto the DCs and then the DC vac-
cine is presented to the immune system via intranodal 
injection(s). The advantage of these whole tumor vac-
cines is that they target a whole range of antigens thus 
reducing the chance of tumor escape compared to single 
epitope vaccines. They are independent of HLA type and 
consist of epitopes for CD8+ cytotoxic T-cells (CTLs) 
and CD4+ T helper (Th) cells, leading to a more integral 
immune response [33]. Previous studies with DC vac-
cines loaded with whole tumor lysate have already dem-
onstrated that patients with measurable disease, in cases 
Keywords: Ovarian cancer, Dendritic cell vaccine, Neoantigen, Neoepitope, Cancer immunotherapy, 
Cyclophosphamide
Page 3 of 10Sarivalasis et al. J Transl Med          (2019) 17:391 
such as non-Hodgkin’s lymphoma [34], melanoma [35], 
or renal cancer [36], may obtain clinical benefit. We also 
reported previously on a vaccine generated using autol-
ogous monocyte-derived DCs pulsed with autologous 
tumor lysate produced from tumor tissue dissociated into 
single cells, oxidized and lysed using freeze–thaw cycles 
[37]. Hypochlorous acid (HOCl) oxidization approach 
has previously been shown to be superior to ultraviolet 
B irradiation or freeze–thaw of tumor lysis, in terms of 
priming T cell responses against tumor antigens in vitro, 
and has shown promise in an OC preclinical model [37]. 
We also showed that it was feasible to produce oxidized 
lysate-pulsed DCs in five patients with OC and to per-
form intranodal injections of this vaccine [37], which 
consisted of ex  vivo-cultured, autologous monocyte-
derived DCs pulsed with oxidized autologous tumor 
lysate [38, 39].
In a phase I trial, the OC-DC vaccine was tested in 25 
patients with platinum-treated, immunotherapy-naïve, 
recurrent ovarian cancer in which study the OC-DC 
treatment injected intranodally was found to be safe, 
feasible, able to induce T cell responses to autologous 
tumor antigen, and was associated with significantly pro-
longed survival [40]. In the cohort receiving the vaccine 
combined with cyclophosphamide and bevacizumab, the 
median progression free survival was 11.1 months com-
pared with 4.1  months in the historical control popula-
tion. Survival at 2  years was 100% for the vaccine plus 
bevacizumab/cyclophosphamide group, while it was only 
40% for patients receiving vaccine and bevacizumab only, 
as well as for control patients receiving bevacizumab 
and cyclophosphamide (p = 0.011), confirming that add-
ing cyclophosphamide to the vaccine could increase 
its effect. The 2-year OS rate for patients responding 
to treatment was 100%, whereas it was 25% for non-
responders. Importantly, only patients with an immune 
response to whole tumor lysate or autologous tumor 
showed clinical benefit [40]. Upon analysis of the periph-
eral blood mononuclear cells (PBMCs) collected pre-
vaccination and after five doses of induction vaccination, 
the frequency of tumor-reactive T cells in the peripheral 
blood was found to increase gradually over time. Further-
more, six patients displayed CD8+ responses on immuni-
zation against one or more neo-epitopes. This study was 
the first to show that vaccination with whole tumor lysate 
loaded DCs elicited a CD8 T cell response to antigens 
derived from private non-synonymous somatic tumor 
mutations. These results demonstrate that personalized 
vaccines using whole tumor lysate can enhance pre-exist-
ing immune responses to NeoAgs as well as rationalize 
the potential combinatorial use of whole tumor lysate 
vaccine followed by NeoAgs targeting to enhance the 
anti-tumor effect of vaccinations [40].
NeoAgs in ovarian cancer
Early preclinical evidence suggested that ovarian can-
cer was unsuitable for NeoAg-specific vaccination [41]. 
Subsequent analysis of human ovarian cancer speci-
mens, however, indicated that ovarian cancer tissues 
may express NeoAgs [42, 43] and that their expres-
sion is associated with better OS [44]. NeoAgs promise 
high specificity but are hard to identify because they are 
mostly patient-specific, and they are mainly rare events 
in a patient cohort. Personalized vaccine design requires 
the identification of each patient’s NeoAg tumor reper-
toire (“mutanome”), which has only been possible in 
recent years due to significant technological advance-
ments such as next-generation sequencing (NGS), anal-
ysis of immunopeptidome by mass spectrometry (MS) 
and development of bioinformatical prediction tools 
[45–48]. Limitations concerning the availability of rela-
tively large sample volumes requested (> 1 g of tissue) and 
the logistics involved in the operation of specialized and 
sophisticated MS instruments have so far hampered the 
integration of immunopeptidomics into routine clinical 
practice. The implementation of an individualized treat-
ment concept based on the mutanome requires both 
highly interdisciplinary research and an innovative drug 
development process [49]. It is therefore unclear at this 
point, whether synthetic vaccines based on private anti-
gens are going to be more effective than whole tumor 
lysate vaccines and could potentially replace them.
Methods/design
A novel approach to therapeutic vaccination 
with enhanced efficacy—PEP‑DC Vaccine
Based on our previous OC-DC study observations, 
the specific recognition and targeting of tumor spe-
cific NeoAgs is a powerful way to further enhance the 
effectiveness of OC-DC vaccine. We will therefore use 
a personalized vaccine consisting of autologous mono-
cyte derived DCs pulsed with personalized peptides 
(PEP-DC) combining tumor-specific NeoAgs and TAAs 
in patients with advanced ovarian cancer. In order to 
validate our hypothesis, patients will be randomized 
to receive either OC-DC or the novel PEP-DC vaccine 
during the initial part of this study; then the OC-DC 
arm will switch over to subsequently receive PEP-DC. 
We are therefore proposing a phase I/II, randomized 
two-cohort, single-center study to compare immuno-
genicity and assess the safety of personalized peptide 
pulsed DC vaccine (PEP-DC) alone, or oxidized tumor 
cell pulsed DC (OC-DC vaccine) followed by PEP-DC 
(PEP-DC2). After the comparative phase of vaccina-
tion (six cycles), all patients will be vaccinated with 
PEP-DC. All vaccines will be administered intranodally 
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and applied in combination with cyclophosphamide in 
patients with OC (Fig. 1).
Based on the patient’s own tumor, epitopes for the PEP-
DC vaccine will be determined and will be identified and 
produced from snapped-frozen tumor specimens and 
blood samples. The tumor specimens are required for 
the production of oxidized whole tumor lysate, for DNA 
and RNA extraction to complete NGS and for elution of 
the HLA binding peptides for MS based immunopep-
tidomics [50, 51]. The blood samples will be used for 
PBMC isolation and HLA-typing. PBMC-derived DNA 
will serve as the germline reference genome in order to 
identify personalized NeoAgs. Genomic variants affect-
ing coding genes that are present in the tumor samples 
and absent from the corresponding blood samples are 
assumed somatic. The NGS data will be analyzed using 
our NeoDisc pipeline [52] to generate personalized refer-
ence databases for each patient. The MS-based immun-
opeptidomics data will be searched against the reference 
database in order to directly identify in  vivo presented 
NeoAg as well as TAAs. In addition, based on these ref-
erences, NeoAg binding to HLA-I and HLA-II molecules 
will be predicted in silico. Eventually, 100 personalized 
targets for each patient will be selected and redesigned 
as ~ 25mer peptides optimally spanning across the pre-
dicted ligands [52].
In order to narrow down the number of target antigens 
to maximum 10 per patient, we have set-up robust T-cell 
assays to test patient’s PBMCs, T cells and TILs for their 
reactivity to private peptides. Using the patients’ iso-
lated CD4 and CD8 T-cells, we will perform functional 
validation of immune reactivity against the 100 candi-
date peptides and quantify it by IFNγ ELISpot assay. 
This additional step allows us to incorporate immuno-
genic antigens into the PEP-DC design to enhance the 
patient’s already existing anti-tumor immune response 
after vaccination, and hence, to increase the vaccine’s 
potential. Following this immunogenicity analysis, the 
targets list will be reduced to 10 target sequences and 
‘enhanced quality’ peptides for the Top 10 targets will be 
ordered from Almac (Edinburgh, UK) for vaccine manu-
facturing. As a few peptides might fail synthesis, up to 
10 targets will be eventually used. The Top 10 peptides 
selected a priori will be used to formulate the PEP-DC 
vaccine for Arm A patients. In Arm B, patients will first 
receive OC-DC vaccine then based on the immunogenic-
ity analysis on PBMCs collected a priori and after three 
OC-DC vaccines (at the end of cycle 3) a personalized 
PEP-DC vaccine will be designed for them. The top 10 
peptides determined at this time point (reflecting new 
immune responses induced by the preceding OC-DC 
vaccines) will be used to formulate the PEP-DC2 vaccine 
to be administered to patients in Arm B after six OC-DC 
administrations.
Fig. 1 Clinical trial study design
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A new dendritic cell vaccine closed system platform
OC-DC vaccine will be manufactured using oxidized 
whole tumor cell lysate derived from autologous tumor 
harvested during laparoscopy surgery or interval debulk-
ing surgery (IDS) pulsed onto autologous dendritic cells. 
The choice of dendritic cell maturation and the choice 
of tumor cell preparation are based on data previously 
published [53]. In this study, the vaccines’ components 
include agents for which safety has previously been 
shown to be acceptable [40].
PEP-DC vaccines will be manufactured and formulated 
at the GMP (good manufacturing practice) facility of the 
Center of Experimental Therapeutics (CTE, Lausanne) 
and the Centre Hospitalier Universitaire Vaudois (CHUV, 
Lausanne). After the Top 10 peptides have been identi-
fied and manufactured, patients will undergo leukapher-
esis for generation of DCs. Autologous monocytes will 
be enriched in a CliniMACS Prodigy (Miltenyi Biotec) 
system that is a GMP-compliant closed system, allow-
ing for standardized and reproducible cellular process-
ing across multiple instruments. The leukapheresis bag 
will be attached using sterile tubing set to the CliniMACS 
Prodigy device, and with the predefined LP-14 enrich-
ment program and the CD14 reagent (magnetic beads, 
Miltenyi Biotec), CD14+ monocytes will be purified by 
positive enrichment. Purified monocytes will be differ-
entiated into immature monocyte-derived DC (iDC) by 
a 5  days culture in the presence of clinical grade IL-4 
and GM-CSF. iDC will then be loaded with a mix of the 
Top 10 peptides overnight and matured/activated for 
6 to 8 h on day 6 using a maturation cocktail consisting 
of clinical grade monophosphoryl lipid A (MPLA) and 
IFNγ. Finally, cells will be harvested and cryopreserved 
as vaccine doses, comprising 5-10  x106 cells per dose. For 
each injection of the PEP-DC vaccine, one dose will be 
thawed, washed and resuspended in NaCl 0.9% supple-
mented with 1% human albumin before being transferred 
into syringes and stored at 2–8 °C until administration to 
patients as intranodal injection.
Using low‑dose cyclophosphamide to enhance immune 
response
In a study of 104 ovarian cancer patients, regulatory T 
cells (Treg) have been shown to contribute to growth of 
human tumors in  vivo [15]. It has been demonstrated 
that low-dose cyclophosphamide, when used in combina-
tion with immunotherapy, can reduce Treg numbers and 
impair their function without eliminating other immune 
cells [54–56], thus creating a favorable environment for 
greater efficacy and immune response. For instance, pre-
treatment with intravenous low-dose cyclophosphamide 
(300  mg/m2) improved immunogenicity of a p53-syn-
thetic long peptide vaccine in patients with recurrent 
OC [57]. Tanyi et al. [58] assessed OC-DC vaccine either 
alone (cohort 1, n = 5) or in combination with bevaci-
zumab (cohort 2, n = 10), or bevacizumab plus low-dose 
intravenous cyclophosphamide (cohort 3, n = 10) in ovar-
ian cancer patients until disease progression or exhaus-
tion of vaccine doses. Low-dose cyclophosphamide 
(200  mg/m2) was administered about 24  h before each 
vaccine dose, and bevacizumab (10 mg/kg) was adminis-
tered on the day of vaccination. The survival observed in 
the cohort with cyclophosphamide was longer than pre-
viously reported in this population with bevacizumab-
based biological combinations [59, 60]. Consistently, in 
our study we will administer intravenous cyclophospha-
mide at a dose of 200  mg/m2 within 24  h prior to each 
vaccination.
Clinical study design
This investigator-initiated trial will be conducted at the 
Department of Oncology at the CHUV. We propose a 
Phase I/II, randomized, two-cohort, single-center study 
in ovarian cancer patients to compare immunogenic-
ity and assess the safety of PEP-DC alone (Arm A) or 
OC-DC vaccine followed by PEP-DC2 (Arm B); vaccines 
will be administered intranodally and in combination 
with cyclophosphamide in all cases. We consider that 
vaccination with synthetic vaccines (PEP-DC and PEP-
DC2) developed on the basis of our integrated tumor 
antigen discovery pipeline is feasible, and can produce 
specific immune responses when applied in combination 
with low dose cyclophosphamide against mutated pep-
tides and other private tumor antigens. The OC-DC vac-
cine therapy is expected to activate and expand T-cells 
that recognize both the NeoAg and shared tumor anti-
gens, and to correlate with clinical benefit. Furthermore, 
we expect OC-DC priming to boost PEP-DC vaccination, 
as we hypothesize that a priori prediction of relevant 
immunogenic peptides is currently not optimal, and that 
upfront vaccination with whole tumor lysates may signifi-
cantly enhance the detection of immunogenic antigens in 
in  vitro T cell assays, and thus assist in the subsequent 
development of synthetic personalized vaccines. A ran-
domization of 1:1 to arm A (PEP-DC) or arm B (OC-
DC followed by PEP-DC2) will be performed to reduce 
potential selection bias on outcome.
Study objectives
The primary objective of the study is to determine the 
immunogenicity of PEP-DC vaccine compared to the 
OC-DC vaccine followed by PEP-DC2 vaccine, specifi-
cally its effect on eliciting/enhancing T-cell responses to 
private epitopes detected by our antigen identification 
algorithm. The secondary objectives of the study include 
the assessment of feasibility, safety, overall survival (OS), 
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time to progression and disease-free survival rates at 12, 
24, and 36 months in the two arms, using both RECIST 
1.1 and CA 125 GCIG criteria. As an exploratory objec-
tive, we will determine whether a priori PEP-DC vaccine 
and OC-DC vaccine followed by PEP-DC2 vaccine elicit 
epitope spreading.
Eligibility criteria and number of patients
Informed consent will be obtained from all participants. 
Eligibility criteria require patients to be 18 years or older, 
with high grade serous ovarian cancer (HGSOC) at FIGO 
stage III or IV who completed either primary debulking 
surgery (PDS) or interval debulking surgery (IDS) with-
out residual disease (R0), and have received either at least 
3 cycles of chemotherapy in the per-operative chemo-
therapy and IDS design, or 6 cycles of platinum-based 
chemotherapy after PDS. A total of 16 evaluable patients 
(8 patients in each arm) is required to enter this small, 
randomized Phase I/II trial, in order to have adequate 
power (at least 80%) for testing, at an alpha of 0.05 for 
differences between the immunogenicity in the two arms.
Regimen
We anticipate that the majority of patients will undergo 
IDS procedure while a small fraction of them will receive 
paclitaxel and carboplatin adjuvant chemotherapy after 
PDS according to the institution’s SoC treatment algo-
rithms. Prior to surgery, ovarian cancer patients will be 
offered the option for collection of surgically debulked 
ovarian tumor tissue and blood sample that will be pro-
cessed in the laboratory for antigen identification under a 
dedicated research protocol.
After enrollment, patients who completed IDS with-
out residual disease will be randomized into either Arm 
A or Arm B while starting their adjuvant chemotherapy 
(Fig.  1). After the last chemotherapy cycle, all rand-
omized patients must undergo a 10–15  L apheresis to 
harvest PBMCs that will be transferred to the Tumor 
Processing Facility at the CTE for DC manufacturing. 
In both trial arms, cyclophosphamide will be adminis-
tered intravenously at a dose of 200 mg/m2 1 day before 
to each vaccination (W1D1 of each cycle). Each dose of 
any DC vaccine (PEP-DC, OC-DC or PEP-DC2) will con-
tain 3–10 × 106 antigen-loaded autologous DCs in a total 
volume of 1 mL and will be delivered as two intranodal 
injections, half dose in each thigh under ultrasound guid-
ance (W1D2 of each cycle).
Patients randomized to Arm A will receive six per-
sonalized PEP-DC vaccinations, the first three every 
3  weeks on Day 2, 23 and 44 (± 3  days), followed by at 
least three more PEP-DC vaccinations administered 
every 4 weeks (± 3 days), except in cycle 6 that will last 
5 weeks (± 3 days). Additional PEP-DC vaccines may be 
administered every 4  weeks (± 3  days) if available, until 
exhaustion of vaccine doses or progression of the disease, 
whichever occurs earlier.
Patients randomized to Arm B will first receive six 
OC-DC vaccines on Q3  W (± 3  days) to induce antitu-
mor immune responses, the first three of them 3 weeks 
apart and from the fourth OC-DC injection onward 
every 4  weeks (± 3  days), or 5  weeks (6th cycle). Based 
on the results of the immunogenicity assay (using blood 
samples collected at baseline and after the third OC-DC 
cycle), the Top 10 antigen targets to be incorporated in 
the PEP-DC2 will be re-prioritized to allow inclusion 
of tumor antigenic targets against which the first three 
OC-DC vaccines induced specific T cell responses. After 
the sixth OC-DC vaccination, patients in Arm B may 
undergo a second leukapheresis during weeks 18–19 
to produce their PEP-DC2 vaccine. Then, patients will 
receive at least six personalized PEP-DC2 vaccines Q4 W 
(± 3 days) until exhaustion of vaccine doses or progres-
sion of the disease, whichever occurs earlier.
Safety, laboratory and imaging assessments
The clinical tumor response will be assessed by serum 
CA-125 measurement, and by computed tomography 
(CT) scans of chest, abdomen and pelvis. A 5-year fol-
low-up counting from the first DC vaccine injection is 
planned. Blood samples will be collected for all patients 
in both arms for the purpose of immune monitoring and 
translational research at screening (for prioritization of 
Top 10 targets), before the 1st vaccine (C1W1D1), after 
the 3rd (C3W3) and 6th (C6W3-W5) OC-DC vaccine, 
then every 12 weeks ± 7 days, at EOT and every 3 months 
in the first year as well as and every 6 months during the 
second year.
Translational analysis
We will test the immunogenicity of the top 100 tumor 
antigens (specific to each patient) in both trial  arms 
using peripheral blood samples from screening (before 
vaccine), before cycle 3, at cycle 6 and 9, as well as at 
EOT in both study arms to detect any improvement or 
change in antigen-specific immune response. We will 
conduct immune landscape analysis of tumor infiltrating 
immune cells using multiplexed immunohistochemistry 
(mIHC) on tumor samples to understand the interactions 
between tumor cells and the immune system within the 
tumor microenvironment. T cells and immune cells will 
be quantified by using lineage specific markers combined 
with functional markers, to assess the activation and dif-
ferentiation status. PBMCs or TILs recognizing the TAAs 
NeoAgs will also be isolated and their TCR sequenced. 
Furthermore, tetramers against TAAs and NeoAgs will 
be synthesized and multicolor flow cytometry will be 
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used to perform an extensive immunophenotyping of 
specific CD4+ and CD8+ cells in TILs and PBMCs col-
lected at different time points. Flow cytometry analyses 
will include markers to assess T cell activation, inhibition, 
differentiation and functionality status. In parallel, mass 
cytometry (CyTOF) will be used to quantify, profile and 
phenotype their activation and functional status as well 
as other immune/stroma populations. For investigation 
of immune fitness, patients’ PBMCs will be interrogated 
with sets of TLR antagonists, antigens and mitogens 
in in  vitro functional assays to quantify the capacity of 
immune cells to respond to different stimuli.
Statistical methods
Safety in both cohorts will be assessed using NCI Com-
mon Terminology Criteria for Adverse Events (CTCAE 
v5.0) from registration until 30 days after the last vaccine 
injection. Efficacy time-to-event endpoints will be evalu-
ated separately by RECIST 1.1 and CA 125 GCIG criteria 
in the two treatment arms, based on the Kaplan–Meier 
method. The safety population includes all evaluable sub-
jects who received at least one vaccine dose. An immu-
nogenicity scoring will be determined as follows: for each 
of the 100 pre-determined peptides, a score will deter-
mine for how many peptides immunogenicity in T-cells 
based assays is newly detected (shift from undetectable to 
detectable) or increased (the frequency of T-cell directed 
against the epitope is increased by ≥ twofold). Immuno-
genicity will be compared between the two vaccine arms, 
at least in two time-points; first at the end of the third 
cycle and second after the sixth vaccine dose.
Discussion
DC-based vaccines were introduced decades ago to 
increase the immunogenicity of cancer vaccines and 
since then have been administered to numerous patients 
with diverse tumor types. They have a favourable toxic-
ity profile and are well-tolerated. As they have shown 
moderate efficacy in the past, we have chosen to apply 
concomitant immuno-modulation in the form of intrave-
nous low-dose cyclophosphamide, which we have already 
tested in combination with intranodal OC-DC vaccine in 
the advanced ovarian cancer population [40]. Intranodal 
injection of DC allows administration of a defined quan-
tity of DCs directly to the site of T-cell sensitization; it 
also allows the peak IL-12 secretion to be synchronized 
with their proximity to T cells, where IL-12 can exert its 
full effects during antigen presentation [61].
When tumor samples are available for vaccine prepa-
ration, different choices may be available for cancer 
vaccine design and the choice of the target antigen is 
critical. Personalized vaccines targeting NeoAgs emerge 
as a promising approach. NeoAgs are more likely to elicit 
strong T-cell responses, because T cell tolerance does not 
hamper their immunogenicity, and consequently epitope 
spreading and a broad anti-tumor immune response. As 
a downside, the process of sequencing, immunopeptid-
omics analysis, peptide manufacturing and GMP manu-
facturing of NeoAg vaccines is long and expensive [26], 
although costs may decrease as a result of technological 
improvements. Currently it is not clear whether NeoAgs 
are superior targets compared with TAAs or tumor cell 
lysates and we believe that vaccinating first with OC-DC 
will lead to the activation of specific T cells against Neo-
Ags included in the PEP-DC vaccine, and hence will 
improve its efficacy.
Despite the rapid progress, the future development 
of DC-based cancer vaccines for wide-ranging clinical 
applications remains difficult. It is costly and is logisti-
cally difficult to be applied to every patient and be widely 
available. However, if this therapy proves to be effective, 
it would not be impossible to deliver it to all patients; 
very similarly to engineered T cells, which have become 
readily available given the recent entry of the pharmaceu-
tical industry to this arena [62]. Furthermore, alternative 
APC platforms are currently under evaluation by many 
investigators worldwide. Another challenge is to assess 
whether DC vaccines can be integrated with SOC chemo 
or radiotherapy in an adjuvant combinatorial treatment 
setting for different types of cancer. The combination of 
such approaches will be a major advancement in cancer 
vaccinology, enabling the development of vaccines with 
enhanced therapeutic efficacy to improve the outcome of 
patients.
Conclusions
We propose a new therapeutic approach to harness anti-
tumor immunity against ovarian cancer, which is innova-
tive in many respects. First, it translates a novel concept 
of NeoAg vaccine delivery from laboratory to the clinic, 
and implements a new personalized and agnostic epitope 
discovery pipeline, that relies on advanced biocomputa-
tional methodologies, exome and RNA sequencing, mass 
spectrometry based immunopeptidomics, and validation 
of the potential epitopes through functional cell-based 
assays. This provides a highly specific target repertoire 
for immunotherapies and increases the chances of induc-
ing a significant and effective immune response against 
established tumors, and the potential for improved effi-
cacy compared to previous vaccines. Second, this study 
is the first attempt to use NeoAg-based vaccines in 
ovarian cancer, specifically in the adjuvant setting. The 
proposed therapy incorporates the beneficial effects of 
pre-treatment with OC-DC before PEP-DC vaccination 
to induce epitope spreading, immune response against a 
wide range of patient-specific antigens and to enhance 
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pre-existing NeoAg-specific T cell clones. Third, there 
was no previous study comparing an autologous DC 
vaccine targeting NeoAgs to tumor lysate vaccines in 
the adjuvant setting in ovarian cancer. Collectively, this 
approach is novel for ovarian cancer, a condition in dire 
need of new therapies.
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